KurCoSmart Effects on People With Type 2 DM

KurCoSmart Effects on People With Type 2 DM: a Randomized, Open Trial

Status

UNKNOWN

Phases

Phase 1Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05407467

Enrollment

Registered

2022-06-07

Start date

2022-06-30

Completion date

2022-09-30

Last updated

2022-06-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Body Weight, Diabetes Mellitus, Type 2, Inflammation, Insulin Resistance

Keywords

curcumin, coconut oil, diabetes mellitus

Brief summary

The investigators aim to evaluate the effect of curcumin and virgin coconut oil extract supplementation on people with type 2 DM, including blood glucose, HbA1c levels, inflammation, body weight and insulin resistance evaluation

Detailed description

The investigators give Kurcosmart supplementation aside from diabetes standard treatment to evaluate its benefits on people with type 2 DM, considering its effect on controlling fasting and prandial blood glucose, reducing HbA1c level, controlling inflammation degree; and repairing insulin resistance

Interventions

DIETARY_SUPPLEMENTCurcumin and virgin coconut oil extract (KurCo Smart)

we give 2 tablets of curcumin and virgin coconut oil extract thrice a day for 30 days and evaluate the result

Study design

Allocation

RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* Confirmed Type 2 DM * Signing consent form

Exclusion criteria

* Pregnant or breastfeeding * Multiple organ failure * History of hypersensitivity reaction to curcumin and virgin coconut oil * Cancer, renal insufficiency, hematological disease, acute heart failure, chronic liver disease

Design outcomes

Primary

Measure	Time frame	Description
Blood glucose	Change of Blood glucose at 1 months	Subject's fasting and prandial blood glucose
Inflammation degree	Change of hs-CRP at 1 Months	Subject's high sensitivity C-reactive protein level
insulin resistance	Change of HOMA IR at 1 Months	Subject's HOMA IR
HbA1c	Change of HbA1C at 1 Months	Subject's glycated haemoglobin level

Secondary

Measure	Time frame	Description
Body Mass Index	Change of BMI at 1 Months	Subject's height and body weight
Blood Pressure	Change fof blood prssure at 1 Months	Subject's blood pressure

Countries

Indonesia

Contacts

Primary ContactNurhasan Agung Prabowo, MD

dr.Nurhasan21@staff.uns.ac.id6282328010430

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026